Aldeyra Therapeutics shares fell 70% after the FDA issued a third rejection for its dry-eye drug, citing a lack of evidence ...

Previously, the Company had received CRLs in November 2023 and April 2025 due to insufficient evidence in addressing the ...

Aldeyra Therapeutics Inc. ALDX shares are tumbling on Tuesday following the U.S. Food and Drug Administration (FDA) update.

After delaying its review, the FDA has rejected Aldeyra Therapeutics’ experimental dry eye disease treatment for the third time. | After delaying its review, the FDA has rejected Aldeyra Therapeutics’ ...

In its complete response letter, the FDA said Aldeyra had failed to demonstrate reproxalap’s efficacy in adequate and ...

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) said it has received a Complete Response Letter from the U.S. Food and Drug Administration rejecting its New Drug Application for reproxalap, a proposed ...

The US Food and Drug Administration (FDA) has issued a Complete Response Letter to Aldeyra Therapeutics for its New Drug Application of reproxalap for the treatment of dry eye dis ...

Shares of Aldeyra Therapeutics fell sharply in premarket trading Tuesday said the U.S. health regulator rejected its dry-eye drug, saying that the company failed to show the treatment works. Shares ...

Instead of whizzing through the open marsh of the Everglades like he usually does, Tristan Tigertail steers his airboat ...

Study reveals that 77% of patients with moderate-to-severe dry eye disease exhibit discordance between clinical signs and symptoms.

ROCHESTER, Minn., March 13, 2026 /PRNewswire/ -- Nanodropper Inc. today announced the launch of the Eye Drop Score, a first-of-its-kind self-check quiz designed to help people who rely on prescription ...

Fluctuating vision is the most frequently cited complaint, exceeding classic discomfort symptoms, and may divert patients toward refractive explanations before DED is recognized and treated.